CDC/Emory/NIH study published in The New England Journal of Medicine adds to growing body of evidence that extensively drug-resistant TB is fueled more by direct transmission than previously thought in high-burden settings. A study published today in The New England Journal of Medicine provides compelling evidence that extensively drug-resistant tuberculosis (XDR TB) is spreading from…
South African Study Provides Compelling New Evidence on Role of Person-to Person Transmission in Drug-Resistant TB Epidemics
January 18, 2017 • By Centers for Disease Control and Prevention
Cross-posted from CDC Global HIV and Tuberculosis
Cross-posted from CDC Global HIV and Tuberculosis
Prevention Studies In 2016 Set the Stage for Progress
January 9, 2017 • By Carl Dieffenbach, Ph.D., Director of the Division of AIDS, NIAID
It is fitting that in the year that we marked the 35th anniversary of the first recognition of what would come to be known as HIV, we’ve taken major steps toward revolutionizing how we could prevent this disease. In 2016 we began four important clinical studies that promise to inform HIV prevention research, which may…
AIDSinfo Adds Investigational Therapeutic HIV Vaccine Information to Website
December 26, 2016 • By AIDSInfo
“What is PRO-140?” “In what phase of study is injectable cabotegravir?” “How do latency-reversing agents work?” Answers to all of these questions can be found in the AIDSinfo Drug Database. The database is a federal resource that includes information on both FDA-approved and investigational HIV-related drugs. Information on more than 50 investigational drugs is available…
Historic HIV Vaccine Clinical Trial: Facebook Live with NIH’s Dr. Dieffenbach
December 2, 2016 • By AIDS.gov
In a Facebook Live interview from Cape Town, South Africa earlier this week, we heard from NIH’s Dr. Carl Dieffenbach about the exciting launch of HVTN 702, a new HIV vaccine clinical trial supported by NIH. The first HIV vaccine efficacy study to launch anywhere in seven years, HVTN 702 is testing whether an experimental…
NIH Statement on World AIDS Day 2016
December 1, 2016 • By Anthony Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health
Cross-posted from NIAID News
Cross-posted from NIAID News
This year, the world marked the 35th anniversary of the first published reports of what would come to be known as HIV/AIDS. This disease has wrought enormous suffering and devastation and caused more than 35 million deaths. Yet today, thanks to remarkable achievements in biomedical science and public health, we have the tools to build…
Watch HIV Vaccine Trial Launch in South Africa Via Facebook Live! This Wednesday!
November 29, 2016 • By AIDS.gov
Director’s Note, Office of HIV/AIDS and Infectious Disease Policy, HHS: Scientific advances have given us the tools we need to end new HIV infections and save lives. But our work is not yet done, either here in the U.S. or around the world. As we approach the observance of World AIDS Day on December 1…
First New HIV Vaccine Efficacy Study in Seven Years Has Begun
November 28, 2016 • By National Institute of Allergy and Infectious Diseases
Cross-posted from NIAID News
Cross-posted from NIAID News
South Africa Hosts Historic NIH-Supported Clinical Trial November 27, 2016 The first HIV vaccine efficacy study to launch anywhere in seven years is now testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults. The study, called HVTN 702, involves a new version of the only HIV vaccine candidate ever shown…
NIH Spotlights HIV Cure Research
November 15, 2016 • By AIDS.gov
In two Facebook Live events from NIAID’s Strategies for an HIV Cure conference this week we learned about advances in HIV cure research from leaders in HIV science. Dr. Fauci Reflects on the State of HIV Cure Research As the third biennial conference got underway on the NIH campus in Bethesda, Maryland, we had the…
